Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsAvMed Adasuve (loxapine) Prior Auth Coverage | Ope…
    Ask Trek AI about this page
    CurrentAvMedPolicy Pub. 100-2

    Adasuve (loxapine) medical prior authorization

    Customize your policy alerts

    Sign up for AvMed Policy Pub. 100-2 alerts

    Get alerted when Policy Pub. 100-2 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This form governs prior authorization and step-edit requests for Adasuve (loxapine aerosol) administered as an outpatient/medical benefit and applies to AvMed members and their prescribing providers.

    Policy Summary
    PayerAvMed
    PolicyAdasuve (loxapine) medical prior authorization
    Policy CodePolicy Pub. 100-2
    Change TypeNo material changes
    Effective Date
    Next Review Date
    Key ActionProvider must attest Adasuve will be administered only in a REMS-enrolled healthcare facility and include signed, complete supporting documentation when submitting prior authorization.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    280maximum dose billed
    12 moinitial authorization duration
    18+minimum age

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    enrolled only
    REMS setting

    Coverage Criteria

    inv-01: Initial Authorization — Covered when ALL of the following are met

    Covered when ALL of the following are met:

    Age: Member is 18 years of age or older>=18 years

    chunk 4

    Diagnosis: Member has a diagnosis of schizophrenia OR bipolar I disorderdiagnosis present

    chunk 5

    Clinical presentation: Member is experiencing psychomotor agitation as defined in DSM-IV or has documentation of agitation interfering with care (e.g., threatening, escalating, or self-exhausting behaviors) warranting use of a rapidly absorbed antipsychoticclinical documentation provided

    chunk 5

    Administration setting (REMS): Provider attests Adasuve will be administered only in a REMS-enrolled healthcare facility to mitigate risk of bronchospasmREMS-enrolled facility

    chunk 5

    Supporting documentation (labs, diagnostics, chart notes) provided for each checked criterion; absence may result in denialcomplete supporting documentation

    chunks 3 and 5

    Quantity limit: Requested dosing does not exceed maximum of 280 billable units per 28 days<=280 units per 28 days

    chunk 3

    inv-02: Reauthorization / Continuation — Reauthorization covered when ALL of the following are met

    Reauthorization covered when ALL of the following are met:

    Continuation of criteria: Member continues to meet ALL initial authorization criteria (age, diagnosis, clinical presentation, REMS administration, documentation, and quantity limits)same as initial

    chunk 4

    Reauthorization duration: Reauthorization granted for 12 months if all initial criteria continue to be met12 months

    chunk 4

    Use of samples to initiate therapy does not meet preauthorization or step-edit criteria and will not be accepted. Previous therapies will be verified through pharmacy paid claims or submitted chart notes; providers should ensure documented evidence of prior treatment is included with the request.

    Requests where the administration is not performed in a REMS-enrolled healthcare facility or that lack documentation confirming the member's diagnosis, documented agitation, and required supporting records (labs, diagnostics, chart notes) may be denied as not medically necessary. Providers must attest that Adasuve will be administered only in an enrolled facility to mitigate the risk of bronchospasm.

    Coding & Quantity Limits

    Covered HCPCS CodeHCPCSCovered
    J2062Injection, loxapine (Adasuve) aerosol powder breath activated (Medical)
    Maximum Dose
    Maximum dose (billing)280 billable units per 28 days
    Reporting periodPer 28 days
    Where documentedListed on the medical prior authorization form under 'Maximum Dose'
    Adasuve (loxapine) quantity limit
    Quantity limit for Adasuve (loxapine)280 billable units per 28 days
    Applies toAdasuve (loxapine) billed as a medical benefit (J2062) per prior authorization form
    Verification

    Provider Actions & Submission Requirements

    Prior Authorization

    Prior Authorization Required

    Adasuve (loxapine aerosol powder, J2062) requires prior authorization when billed as a medical benefit. Requests must include a signed prescribing physician signature (preprinted stamps not valid). Incomplete, incorrect, or illegible submissions may delay or result in denial of authorization. For urgent reviews, contact AvMed Pre-Authorization if a standard review could seriously jeopardize the member's life, health, or function.

    • Prior authorization required for Adasuve billed as J2062 (Medical).
    • Fax completed request and supporting documentation to 1-877-535-1391.
    • Prescriber signature required; preprinted stamps are not valid.
    • Urgent review: contact AvMed Pre-Authorization per plan definition.
    Step Therapy

    Samples and Prior Therapy Verification

    Use of product samples to initiate therapy does not satisfy step-edit or preauthorization requirements. The provider must document prior therapies — previous treatments will be verified via pharmacy paid claims or submitted chart notes.

    Definitions

    Psychomotor agitation
    DSM‑IV definition (as used in policy)'Excessive motor activity associated with a feeling of inner tension'
    Policy applicationIndicates agitation severe enough to warrant rapidly absorbed antipsychotic treatment (e.g., behaviors interfering with care such as threatening, escalating, or self‑exhausting behavior)
    Documentation requirementProvider must submit documentation confirming the presence of psychomotor agitation (chart notes, diagnostics) for each checked criterion
    Role in approvalMember must be experiencing psychomotor agitation (per DSM‑IV definition) for initial authorization to be approved

    Initial Therapy Criteria

    inv-14: Initial Therapy Criteria — initial authorization logic

    Initial Authorization

    Age and diagnosis: Member is >=18 years of age AND has a diagnosis of schizophrenia OR bipolar I disorder with documented psychomotor agitation>=18; documented diagnosis and agitation

    chunks 4 and 5

    Clinical documentation of agitation: Provider has submitted documentation confirming agitation that interferes with care (e.g., threatening, escalating, or self-exhausting behaviors) leading to the use of a rapidly absorbed antipsychoticclinical documentation provided

    chunk 5

    Facility and REMS: Provider attests Adasuve will be administered only in a REMS-enrolled healthcare facility

    Continuation / Reauthorization Criteria

    inv-15: Continuation Therapy — reauthorization criteria logic

    Reauthorization

    Continuation criteria: Member continues to meet ALL initial authorization criteriasame as initial

    chunk 4

    Reauthorization duration: When criteria are met, reauthorization is granted for 12 months12 months

    chunk 4

    Step Therapy Requirements

    StepRequirement
    1Previous therapies must be verified through pharmacy paid claims or submitted chart notes; use of samples to initiate therapy does not satisfy the step-edit/preauthorization requirement.

    Site of Care / REMS Requirements

    Note

    Administration only in REMS-enrolled facility (office, infusion center, hospital outpatient)

    Adasuve must be administered only in a REMS-enrolled healthcare facility (office, infusion center, or hospital outpatient) to mitigate the risk of bronchospasm; the provider must attest to facility enrollment on the request.

    • Permitted administration settings: physician office, infusion center, or hospital outpatient
    • Provider attestation that administration will occur in a REMS-enrolled facility is required

    Background

    Adasuve (loxapine inhalation powder) is a rapidly absorbed antipsychotic indicated for acute agitation associated with schizophrenia or bipolar I disorder. Because inhaled loxapine can cause bronchospasm, its use is restricted to administration in REMS-enrolled healthcare facilities and providers must attest to facility enrollment when requesting coverage.

    Policy Summary
    PayerAvMed
    PolicyAdasuve (loxapine) medical prior authorization
    Policy CodePolicy Pub. 100-2
    Change TypeNo material changes
    Effective Date
    Next Review Date
    Key ActionProvider must attest Adasuve will be administered only in a REMS-enrolled healthcare facility and include signed, complete supporting documentation when submitting prior authorization.
    SourceLink
    On This Page
    Coverage CriteriaCoding & Quantity LimitsProvider Actions & Submission RequirementsDefinitionsInitial Therapy CriteriaContinuation / Reauthorization CriteriaStep Therapy RequirementsSite of Care / REMS RequirementsBackground
    Quantity monitored via medical billing claims and prior authorization review
    • Samples do NOT meet step-edit/preauthorization criteria.
    • Prior therapy will be verified through pharmacy claims or chart documentation.
    Documentation Required

    Required Submission Contents

    All authorization requests must include the following: provider’s printed name and original signature, member and prescriber information, diagnosis, and supporting clinical documentation (e.g., chart notes, lab results, diagnostics) to justify the use of Adasuve for psychomotor agitation or approved diagnoses.

    • Provider signature and printed name (signature must be original).
    • Member name, ID, and prescriber contact information (phone/fax).
    • Diagnosis (schizophrenia or bipolar I disorder) and documentation of psychomotor agitation where applicable.
    • Supporting documentation: chart notes, labs, diagnostics as relevant.
    Denial Risk

    Incomplete or Illegible Submission

    If the request form or supporting documentation is incomplete, illegible, or missing required elements, the authorization may be delayed or denied. Ensure all phone and fax numbers on the form are correct to avoid unnecessary delays.

    • Incomplete, incorrect, or illegible submissions may delay or result in denial of authorization.
    • Ensure phone and fax numbers are accurate on the submission form.
    Documentation Required

    Missing Clinical Documentation or REMS Compliance

    Because loxapine (Adasuve) is subject to a REMS program for bronchospasm risk, requests missing documentation of REMS-compliant administration at an enrolled healthcare facility or lacking confirmation that the administering facility is REMS-certified may be denied.

    • Requests lacking REMS facility confirmation or required REMS documentation may be denied.
    • Adasuve must be administered only in an enrolled healthcare facility per REMS requirements.
    REMS-enrolled facility

    chunk 5

    Dose limit: Requested therapy does not exceed the maximum of 280 billable units per 28 days<=280 units/28 days

    chunk 3